{
    "id": "dbpedia_1753_2",
    "rank": 93,
    "data": {
        "url": "https://www.novonordisk.com/",
        "read_more_link": "",
        "language": "en",
        "title": "driving change to defeat serious chronic diseases",
        "top_image": "https://www.novonordisk.com/content/dam/nncorp/global/en/science-and-technology/images/oxford/close-up-hands-working-in-lab-by-John-Cairns.jpg",
        "meta_img": "https://www.novonordisk.com/content/dam/nncorp/global/en/science-and-technology/images/oxford/close-up-hands-working-in-lab-by-John-Cairns.jpg",
        "images": [
            "https://www.novonordisk.com/content/dam/nncorp/global/en/annual-report/images/2023/ar-2023-front-cover.jpg.corpimgw.1280.1280.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.",
        "meta_lang": "en",
        "meta_favicon": "/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico",
        "meta_site_name": "Novo Nordisk",
        "canonical_link": "https://www.novonordisk.com/",
        "text": "Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024\n\nEuropean regulatory authority adopts a positive opinion for an update of the WegovyÂ® label to reflect risk reduction of major adverse cardiovascular events\n\nHere are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile."
    }
}